SINOVAC Joins Hands with UdeA to Boost Biomedicine R&D in Colombia

October 21, 2022, Beijing -- Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that the Company and the University of Antioquia (UdeA) have signed a memorandum of understanding (MOU) aimed at jointly improving the biomedical research and development capacities in Colombia, demonstrating the Company's contribution to advancing Latin American's public healthcare.

According to the MOU, the two parties agree to enhance the exchange of information and technical know-how related to vaccines and therapeutics to promote scientific studies on immunology and microbiology, develop groups of local young talent, and integrate basic and applied immunology into new vaccines, diagnostics and treatments for infectious diseases, etc.

SINOVAC and the University are also considering the establishment of a vaccine research and development center, which will focus on teaching and performing cutting-edge scientific research in the field of vaccines, immunology and infectious diseases.

Colombia approved SINOVAC's COVID-19 vaccine, CoronaVac^®, for emergency use since February 2021 and was among the first group of countries to adopt the vaccine. More than 27 million doses of the vaccine have been distributed to the country so far, which effectively fills the local vaccination gap with safe and affordable products.

The University of Antioquia, one of the top public universities in the country, plays an important role in Colombia's development of scientific studies, such as immunology, microbiology, medicine, pharmaceutical chemistry. Based on both parties' strengths and resources, the collaboration will effectively help to address the current healthcare challenges locally.

About SINOVAC

Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A and B, seasonal influenza, pneumococcal disease, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella, mumps, poliomyelitis, etc.

The COVID-19 vaccine, CoronaVac^®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive^®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive^®, is an innovative vaccine commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) was prequalified by the WHO.

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1^®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu^®, to the Chinese government stockpiling program.

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.

For more information, please see the Company’s website at www.sinovac.com.

Contact:

Sinovac Biotech Ltd.

PR Team

pr@sinovac.com